Aardvark Therapeutics Hosts Investor Webinar on Drug Programs

Aardvark Therapeutics, Inc. ( (AARD) ) has issued an update.

On November 5, 2025, Aardvark Therapeutics, Inc. held an investor webinar to discuss its ARD-101 and ARD-201 programs and their presentations at ObesityWeek 2025. The company is positioning itself for growth by targeting rare metabolic diseases and obesity through innovative oral drugs that suppress hunger. The ongoing and upcoming clinical trials, including the Phase 3 HERO trial and Phase 2 POWER and STRENGTH trials, aim to expand treatment options and improve patient outcomes. These developments highlight Aardvark’s commitment to addressing severe unmet medical needs and enhancing its market position.

The most recent analyst rating on (AARD) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page.

Spark’s Take on AARD Stock

According to Spark, TipRanks’ AI Analyst, AARD is a Underperform.

Aardvark Therapeutics, Inc. faces severe financial challenges typical of early-stage pharmaceutical companies, with zero revenue and substantial operational losses. The lack of technical and valuation indicators further contributes to the high-risk profile.

To see Spark’s full report on AARD stock, click here.

More about Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapeutic solutions for metabolic diseases and obesity. The company is advancing its pipeline with investigational drugs like ARD-101 and ARD-201, which target hunger and metabolic pathways, addressing unmet needs in conditions such as Prader-Willi Syndrome and obesity.

Average Trading Volume: 168,764

Technical Sentiment Signal: Strong Sell

Current Market Cap: $212.6M

Learn more about AARD stock on TipRanks’ Stock Analysis page.